Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis

被引：0
|
作者：
Schultz, R. [1 ]
Diakite, I. [2 ]
Carter, J. [2 ]
Snedecor, S. [2 ]
Turpin, R. [3 ]
机构：
[1] Takeda Pharmaceut USA Inc, Gastroenterol, Deerfield, IL USA
[2] Pharmerit Int, Gastroenterol, Bethesda, MD USA
[3] Takeda Pharmaceut USA Inc, Gastroenterol, Lake Zurich, IL USA
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P607
引用
收藏
页码：S508 / S508
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis
    Diakite, I.
    Schultz, B.
    Carter, J.
    Snedecor, S.
    Turpin, R.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S454 - S455
  • [2] COST-EFFECTIVENESS OF VEDOLIZUMAB IV VERSUS ADALIMUMAB SC FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Schultz, Robert
    Diakite, Ibrahim
    Carter, John A.
    Snedecor, Sonya
    Turpin, Robin S.
    GASTROENTEROLOGY, 2020, 158 (06) : S658 - S658
  • [3] Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
    Schultz, Bob G.
    Diakite, Ibrahim
    Carter, John A.
    Snedecor, Sonya J.
    Turpin, Robin
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (11): : 1592 - 1600
  • [4] Cost-Effectiveness of Adalimumab in Moderately to Severely Active Ulcerative Colitis
    Ali, Tauseef
    Skup, Martha
    Yang, Mei
    Yang, Min
    Wu, Eric
    Mulani, Parvez
    Chao, Jingdong
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S641 - S641
  • [5] COST-EFFECTIVENESS OF ADALIMUMAB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN CANADA
    Ghosh, S.
    Desjardins, O.
    Skup, M.
    Wang, S.
    Yang, M.
    Yang, H.
    Qi, C.
    Bao, Y.
    Chao, J.
    VALUE IN HEALTH, 2014, 17 (03) : A37 - A37
  • [6] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH INFLIXIMAB, ADALIMUMAB, AND GOLIMUMAB FOR TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM
    Wilson, M.
    Kerrigan, M.
    Smyth, M.
    Chevrou-Severac, H.
    Bergman, A.
    Selby, R.
    GUT, 2016, 65 : A260 - A261
  • [7] COST-EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN RUSSIA
    Pyadushkina, E.
    Derkach, E., V
    VALUE IN HEALTH, 2017, 20 (09) : A635 - A635
  • [8] Comparative Efficacy and Safety of Ozanimod vs Adalimumab and Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis
    Dubinsky, Marla C.
    Betts, Keith A.
    LaPensee, Kenneth
    Eren, Devrim
    Kim-Romo, Dawn
    Yin, Lei
    Tang, Wenxi
    Gupte-Singh, Komal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S314 - S314
  • [9] Cost-Effectiveness of Vedolizumab Compared With Conventional Therapy and Biologics for Treatment of Moderately to Severely Active Ulcerative Colitis in the United States
    Wilson, Michele
    Mody, Reema
    Ursan, Iulia
    Carr, Sean
    GASTROENTEROLOGY, 2015, 148 (04) : S198 - S199
  • [10] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY FOR TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM
    Wilson, M.
    Kerrigan, M.
    Smyth, M.
    Chevrou-Severac, H.
    Bergman, A.
    Selby, R.
    GUT, 2016, 65 : A260 - A260
12345